Chinese FDA Imposes Mandatory Electronic Barcoding on Imported Drugs


The State Food and Drug Administration (“SFDA”) issued a Notice on Relevant Issues Concerning Imposing Electronic Barcoding on Imported Drugs (“Notice”) on January 29, 2013 with immediate effect. Pursuant to the Notice, manufacturers of imported narcotics, psychotropic drugs, blood products, vaccines, injectables made by Traditional Chinese Medicines (“TCM”), and drugs listed on the national or provincial Essential Drug Lists (“EDL”) must affix electronic barcodes to the external packages of the imported drugs at the offshore manufacturing facilities indicated on the respective import drug licenses. If the imported drugs are approved for domestic re-packaging in China, the affixture of electronic barcodes can be completed by the licensed re-packaging entity. Photos or packaging samples demonstrating proper affixture of electronic barcodes must be included in the submission for import registration with the local FDA at the port of entry. Imported drugs subject to the Notice will be denied import registration if they do not bear the electronic barcodes by January 1, 2014.

Manufacturers of imported drugs subject to the Notice can appoint a pharmaceutical manufacturer, a pharmaceutical distributor or its affiliates in China to act as the local agent to coordinate electronic barcoding. Such local agent shall file for a record with the Administrative Services Center of the SFDA and will be responsible for applying for electronic barcodes, entering relevant information in the SFDA’s database and managing product recalls on behalf of manufacturers. Changes in relation to the local agents or termination of the appointment shall be reported within five working days with the SFDA’s Administrative Services Center.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.